Medra raises $52M Series A to build Physical AI Scientists for drug discovery
Evidence notes
- Series A led by Human Capital with participation from Lux Capital, Neo, NFDG, Catalio Capital Management, Menlo Ventures, 776, and Fusion Fund
- Funding supports team growth, partnership scaling, and construction of a large-scale autonomous lab planned for 2026
- Medra combines scientific AI with robotic execution to run experiments on standard laboratory tools and instruments
Company context
Medra builds autonomous robotic lab systems for life-sciences research. Its Physical AI Scientist platform combines robotic workcells, lab perception and scientific AI to run protocols, operate instruments and improve experiments across biology and chemistry workflows.